Clinical trial
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
NCT00320424 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320424 |
|---|---|
| Title | Hip Fracture Study of GSK576428 (Fondaparinux Sodium) |
| Official title | Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | Fondaparinux |
| Enrollment | 48 |
| Start date | Feb 16, 2006 |
| Primary completion | Oct 26, 2006 |
| Completion | Oct 26, 2006 |
| First posted | May 3, 2006 |
| Last update posted | Sep 4, 2018 |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: